The study find that the  the microenvironment of the tissue in which they are find. Therefore Researchers at Karolinska Institutet have mapped the stem-cell niche in the bone marrow of mice and studied how it is influenced by developing leukemia. Because Their results; which are publish in the journal Cell’; show that the bone-marrow microenvironment is more complex than expect and contribute knowledge to future therapies for the disease.

The bone marrow of mice

The environment that protects and regulates the stem cells in body tissues is call the stem-cell niche and consists, in part; of a type of structural tissue called the stroma. But The stroma has not yet been fully characterize and only a few specific stromal cell types have been describe.

Researchers at Karolinska Institutet and their colleagues David Scadden at Harvard University and Aviv Regev at Broad Institute have now study and describe the mouse bone-marrow stroma and how it changes in the presence of leukemia. Their results are publish in the journal Cell.

Few specific stromal cell

He began the project as a postdoc at Harvard University and conclude it at Karolinska Institutet. Therefore The study is base on the single-cell analysis technique; which makes it possible for scientists to study individual cells and characterize them to a high level of detail. In the mouse bone-marrow stroma; the researchers found 17 different cell populations, which they could break down into a number of unique cell types.

“They found over 30 cell types with different functions in the bone-marrow microenvironment;” says Dr Baryawno. Therefore By using a mouse model that develops acute myeloid leukemia (AML); the researchers were able to examine how the disease changes the bone-marrow microenvironment. One finding is that the bone stem cells and the production of stem-cell factors for hematopoiesis (blood development) are block during the development of the disease.

Bone-marrow microenvironment

“Our work provides empirical corroboration for how cancer cells communicate with specific stromal cells to corrupt normal tissue function and to enable tumor growth;” he continues. “It also provides insight into how cancer cells change stroma on several levels, both cellular and molecular; which suggests that the treatment of leukemia must target several fronts.”

The study was financed with grants from the Swedish Research Council and the Swedish Childhood Cancer Foundation. It was also supported by the National Institutes of Health, the Howard Hughes Medical Institute, the Charles A. King Trust Postdoctoral Research Fellowship Program; the Simeon J. Fortin Charitable Foundation, the Klarman Cell Observatory and the Gerald and Darlene Jordan Professorship.

Many of the authors have links to different drug or technology companies through share ownership; consultancy work or employment. See the article for further details. Because The researchers have submitted an application to patent their results.